|
22 Melton St. London NW1 2BW, United Kingdom Tel. +44-20-7691-3583 Fax +44-20-7419-4653 |
Type: Public
On the web:
http://www.lipoxen.co.uk
Lipoxen does its part to give the fight against the cancer pox a shot in the arm. The biopharmaceutical company specializes in oncology treatments using proprietary technology (PolyXen) designed to naturally increase the stability, biological half-life, and immunologic characteristics of therapeutics. The company also uses liposomal technology for the development of cytotoxic drugs, pneumococcal vaccines, and other anti-cancer agents. Its proprietary vaccine delivery technology, ImuXen, uses the same liposomal formation method to administer shots to the immune system in a way that mimics a natural encounter with the offending disease.
Key numbers for fiscal year ending December, 2008:
Sales: $1.7M
One year growth: (7.1%)
Net income: ($5.0)M
Officers:
Chairman: Sir Brian M. Richards
CEO: M. Scott Maguire
COO: Peter Laing
Competitors:
3M Health Care Ltd
Cancer Research Technology
CytRx




